Details of the Drug
General Information of Drug (ID: DMAQOL0)
Drug Name |
3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
72818-36-1; UK 34787; UK-34787; CHEMBL284356; 3-(1h-imidazol-1-ylmethyl)-2-(propan-2-yl)-1h-indole; 3-(imidazol-1-ylmethyl)-2-propan-2-yl-1H-indole; 3-Isopropyl-3-(1-imidazolylmethyl)indole; AC1L4YBG; 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole; AC1Q4X5Y; SCHEMBL11346119; CTK5D6874; DTXSID00223136; NZXGMVRYQLENHC-UHFFFAOYSA-N; BDBM50022121; NSC342229; AKOS030539398; NSC-342229; 3-(imidazol-1-ylmethyl)-2-isopropylindole; 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole(UK-34787); 1H-Indole, 3-(1H-imidazol-1-ylmethyl)-2-(1-methylethy
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 239.32 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||